|
1
|
Knezevic T, Myers VD, Su F, Wang J, Song J, Zhang XQ, Gao E, Gao G, Muniswamy M, Gupta MK, Gordon J, Weiner KN, Rabinowitz J, Ramsey FV, Tilley DG, Khalili K, Cheung JY, Feldman AM. Adeno-associated Virus Serotype 9 - Driven Expression of BAG3 Improves Left Ventricular Function in Murine Hearts with Left Ventricular Dysfunction Secondary to a Myocardial Infarction. ACTA ACUST UNITED AC 2016; 1:647-656. [PMID: 28164169 PMCID: PMC5289821 DOI: 10.1016/j.jacbts.2016.08.008] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
BAG3 is a highly conserved protein having pleiotropic effects that is expressed at high levels in the heart, skeletal muscles, and many cancers. BAG3 levels are reduced in many forms of LV dysfunction including mice after ligation of the left coronary artery. Retro-orbital injection of mice with an adeno-associated virus coupled to murine BAG3 under the control of a CMV promoter (rAAV9-BAG3) increased myocardial levels of BAG3 by 7 days post-injection. Retro-orbital injection of rAAV9-BAG3 in mice post-myocardial infarction improved LV function, whereas rAAV9-BAG3 had no effect on LV function in the absence of an MI. BAG3 may prove to be a new therapeutic target in the treatment of heart failure.
Mutations in Bcl-2–associated athanogene 3 (BAG3) were associated with skeletal muscle dysfunction and dilated cardiomyopathy. Retro-orbital injection of an adeno-associated virus serotype 9 expressing BAG3 (rAAV9-BAG3) significantly (p < 0.0001) improved left ventricular ejection fraction, fractional shortening, and stroke volume 9 days post-injection in mice with cardiac dysfunction secondary to a myocardial infarction. Furthermore, myocytes isolated from mice 3 weeks after injection showed improved cell shortening, enhanced systolic [Ca2+]i and increased [Ca2+]i transient amplitudes, and increased maximal L-type Ca2+ current amplitude. These results suggest that BAG3 gene therapy may provide a novel therapeutic option for the treatment of heart failure.
Collapse
Affiliation(s)
- Tijana Knezevic
- Department of Biology, College of Science and Technology, Temple University, Philadelphia, Pennslyvnaia; Department of Neuroscience, the Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
| | - Valerie D Myers
- Department of Medicine, the Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
| | - Feifei Su
- Department of Medicine, the Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania; Department of Cardiology, TangDu Hospital, Fourth Military Medical University, Xi'an, China
| | - JuFang Wang
- Center for Translational Medicine, the Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
| | - Jianliang Song
- Center for Translational Medicine, the Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
| | - Xue-Qian Zhang
- Center for Translational Medicine, the Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
| | - Erhe Gao
- Center for Translational Medicine, the Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
| | - Guofeng Gao
- Department of Medicine, the Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
| | - Madesh Muniswamy
- Center for Translational Medicine, the Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
| | - Manish K Gupta
- Department of Neuroscience, the Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
| | - Jennifer Gordon
- Department of Neuroscience, the Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
| | - Kristen N Weiner
- Department of Medicine, the Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
| | - Joseph Rabinowitz
- Center for Translational Medicine, the Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
| | - Frederick V Ramsey
- Department of Biology, College of Science and Technology, Temple University, Philadelphia, Pennslyvnaia
| | - Douglas G Tilley
- Center for Translational Medicine, the Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
| | - Kamel Khalili
- Department of Neuroscience, the Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
| | - Joseph Y Cheung
- Department of Medicine, the Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania; Center for Translational Medicine, the Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
| | - Arthur M Feldman
- Department of Medicine, the Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
| |
Collapse
|
|
2
|
Kemppainen JK, O'Brien L, Williams H, Evans L, Weiner KN, Holzemer WL. Quantifying patient engagement with nurses: validation of a scale with AIDS patients. Outcomes Manag Nurs Pract 1999; 3:167-74. [PMID: 10876542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
The purpose of this study was to develop and test a measure of patient engagement with nurses, which is a quantifiable outcome of nurse-patient encounters. This measure, based on verbatim patient statements, was tested with a multi-site sample of 162 hospitalized patients with acquired immune deficiency syndrome (AIDS). Although developed and tested with acutely ill AIDS patients, the scales are not AIDS specific and hold promise as a general measure of the outcomes of nurse-patient encounters in other acute and chronic illnesses.
Collapse
|